BioCentury | Jul 20, 2018
Clinical News

FDA approves J&J's Symtuza for HIV-1 infection in adults

...FDA approved Symtuza darunavir/cobicistat/emtricitabine/tenofovir alafenamide from Johnson & Johnson (NYSE:JNJ) to treat HIV-1 infection in adults who...
...Symtuza darunavir/cobicistat/emtricitabine/tenofovir alafenamide Business: Infectious Jaime De Leon Prezista (Brand), TMC114 (Compound #), darunavir (Generic), Prezista (Informal) Symtuza (Brand), Darunavir/cobicistat/emtricitabine/tenofovir alafenamide...
...Business: Infectious Jaime De Leon Prezista (Brand), TMC114 (Compound #), darunavir (Generic), Prezista (Informal) Symtuza (Brand), Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Generic), Symtuza...
BioCentury | Oct 27, 2017
Clinical News

EC approves Symtuza for HIV-1, Janssen submits NDA to FDA

...& Development LLC unit submitted an NDA to FDA for a once-daily fixed-dose combination of darunavir/cobicistat/emtricitabine/tenofovir alafenamide...
...12 and older. Also in September, the European Commission approved the combination under the name Symtuza...
...Foster City, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Symtuza darunavir/cobicistat/emtricitabine/tenofovir alafenamide Business: Infectious Meghan Sullivan Symtuza Gilead Johnson...
BioCentury | Sep 19, 2016
Clinical News

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide regulatory update

...Janssen-Cilag International N.V. unit submitted an MAA to EMA for a once-daily fixed-dose combination of darunavir/cobicistat/emtricitabine/tenofovir alafenamide...
Items per page:
1 - 3 of 3